Advice
Following an abbreviated submission
budesonide rectal foam (Budenofalk®) is accepted for use within NHS Scotland for the treatment of active ulcerative colitis that is limited to the rectum and the sigmoid colon.
It should be used in patients for whom rectally administered budesonide is an appropriate choice of treatment. It costs less than equivalent doses of the other rectal formulation of budesonide.
Download detailed advice24KB (PDF)
Medicine details
- Medicine name:
- budesonide 2mg Rectal Foam (Budenofalk)
- SMC ID:
- 409/07
- Indication:
- Ulcerative colitis
- Pharmaceutical company
- Dr Falk Pharma UK
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 08 October 2007